Published in Cancer Weekly, January 21st, 2003
This randomized, controlled study, known as the SMART (study of neurologic progression with motexafin gadolinium and radiation therapy) trial, is designed to enroll 550 patients at over 100 leading medical centers in the United States, Canada, Europe, and Australia. It will compare the effects of whole brain radiation therapy (WBRT) alone to WBRT plus Xcytrin. The primary efficacy endpoint...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.